Durect gets FDA fast track designation for alcoholic hepatitis


Durect’s (NASDAQ:DRRX) DUR-928 received FDA fast track designation for the treatment of alcoholic hepatitis (AH), a life-threatening form of alcohol-associated liver disease. 

In August 2020, Durect reported results of a Phase 2a dose escalation trial evaluating doses of 30 mg, 90 mg, or 150 mg of DUR-928 in alcoholic hepatitis patients. An 89% response rate was observed in all patients, and patients receiving 30 mg or 90 mg doses of DUR-928 had a 100% treatment response rate.  

“Fast track designation highlights the life-threatening nature of alcoholic hepatitis and the lack of therapeutic options for this devastating condition,” Norman Sussman, M.D., Durect’s CMO, said in a statement. 

“As an endogenous epigenetic regulator, DUR-928 is a new class of therapeutics. We are very encouraged by the promising clinical data from our Phase 2a trial in which 100% of AH patients treated with DUR-928 survived the 28-day follow-up period compared to a 26% historical 28-day death rate.”

Durect plans to initiate a Phase 2b trial evaluating DUR-928 for the treatment of alcoholic hepatitis in the coming months.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.